Ovid Therapeutics Inc.
OVID· Nasdaq
Released Aug 7, 2019, after the close
10-Q filed Aug 7, 2019, 38 days after period end · 0001564590-19-030178
| Metric | Q2 2019 | Q2 2018 | Q2 2017 | Q2 2016 |
|---|---|---|---|---|
| Net Income | -$13.06M | -$12.94M | -$10.25M | -$5.39M |
| EPS Diluted | -$0.34 | -$0.53 | -$0.57 | -$0.55 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ovid Therapeutics Inc. · CIK 1636651 · Engraved from SEC EDGAR